[HTML][HTML] Diagnostic and Prognostic Value of microRNAs in Patients with Laryngeal Cancer: A Systematic Review

E Broseghini, DM Filippini, L Fabbri, R Leonardi… - Non-coding RNA, 2023 - mdpi.com
Laryngeal squamous cell cancer (LSCC) is one of the most common malignant tumors of
the head and neck region, with a poor survival rate (5-year overall survival 50–80%) as a …

Modifications induced by the thermal treatment of kaolin and determination of reactivity of metakaolin

B Fabbri, S Gualtieri, C Leonardi - Applied Clay Science, 2013 - Elsevier
Three commercial powdered kaolins were analyzed in order to determine their chemical
and mineralogical compositions, other than physical characteristics such as grain size …

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised …

…, V Labonia, G Landi, A Latorre, V Leonardi… - The Lancet …, 2018 - thelancet.com
Background Uncertainty exists about the optimal schedule of adjuvant treatment of breast
cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the …

T-DM1 and brain metastases: clinical outcome in HER2-positive metastatic breast cancer

…, R Rossello, A Fabbri, A Zambelli, V Leonardi… - The Breast, 2018 - Elsevier
Background We reported the results of an Italian large retrospective analysis that evaluated
the effectiveness and safety of T-DM1 in ‘field-practice’ breast cancer patients. We performed …

Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment

…, G Feldman, C Scott-Wilson, S Kilbride, L Fabbri… - 2012 - Eur Respiratory Soc
Rationale: FF/VI is a novel once-daily (OD) inhaled corticosteroid/long-acting beta 2 agonist
in development as combination therapy for COPD. Objective: To evaluate the efficacy and …

[HTML][HTML] Efficacy and safety of T-DM1 in the 'common-practice'of HER2+ advanced breast cancer setting: a multicenter study

…, M Ciccarese, R Rossello, G Arpino, V Leonardi… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment
of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic …

Erice 2018 Charter on the role of the National Health Service in the prevention of doping

…, E Cadua, A Landi, P Lemma, F Leonardi… - ANNALI DI IGIENE …, 2019 - air.unipr.it
The Erice 2018 Charter was unanimously approved at the conclusion of the 53rd Residential
Course of the International School of Epidemiology and Preventive Medicine" Adapted …

Definition of the DNA-binding specificity of TTF-1 homeodomain by chromatographic selection of binding sequences

D Fabbro, G Tell, L Pellizzari, A Leonardi… - Biochemical and …, 1995 - Elsevier
The homeodomain of the thyroid transcription factor-1 (TTF-1HD) shows a peculiar DNA-binding
specificity, preferentially recognizing sequences having the 5′-CAAG-3′ core motif. …

Nel corpo del Medioevo: la storia, la fede, la poesia: Medioevo latino e cultura europea: in ricordo di Claudio Leonardi a dieci anni dalla sua morte: cronaca del …

F De Luca, A Fabbri, L Maranesi… - … ricordo di Claudio Leonardi …, 2020 - torrossa.com
* Il lavoro, cui hanno partecipato studenti della LM-14/15, è parte integrante del programma
di potenziamento promosso nell’ambito degli insegnamenti di Letteratura latina medievale e …

In the TTF-1 homeodomain the contribution of several amino acids to DNA recognition depends on the bound sequence

D Fabbro, G Tell, A Leonardi, L Pellizzari… - Nucleic acids …, 1996 - academic.oup.com
The thyroid transcription factor-1 homeodomain (TTF-1HD) shows a peculiar DNA binding
specificity, preferentially recognizing sequences containing the 5′-CAAG-3′ core motif. …